Breast Cancer Genetics, Immunology, and Immunotherapy (Record no. 29550)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03550nam a22002657a 4500 |
| 001 - CONTROL NUMBER | |
| control field | 20241102100521.0 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20241102100942.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241102b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 978-3-031-65807-5 |
| International Standard Book Number | 978-3-031-65808-2 (eBook) |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 2731-4561 |
| International Standard Serial Number | 2731-457X (electronic) |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | ddc |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Fuller form of name | Nima Rezaei |
| 222 ## - KEY TITLE | |
| Key title | activity adjuvant angiogenesis antibody anticancer antigen antitumor apoptosis associated BC biomarkers BRCA1 breast cancer cells breast cancer treatment breast tumor cancer therapy CAR-T cell carcinoma CD8+ cellular chemokine chemotherapy Chen cisplatin Clin clinical trials co-delivery combination cytokines cytotoxic delivery disease DNA docetaxel doxorubicin drug resistance effects efficacy enhanced estrogen evaluation everolimus expression fulvestrant G gene genetic genomic H HER2 HER2-positive HER2+ hormone Huang immune response immune system Immunol immunosuppressive immunotherapy induce infiltration inhibition invasion kinase lapatinib Liu lymphocytes macrophages mechanisms metastasis metastatic metastatic breast cancer microRNA miRNAs Mol molecular molecules mutations nanoparticles negative breast cancer neoadjuvant neutrophils Oncol oncolytic virotherapy oncolytic viruses outcomes overexpression paclitaxel pembrolizumab phase potential precision medicine prognostic proliferation promote protein risk RNA role Sci siRNA strategies stromal TILS subtypes suppressor survival T-cell tamoxifen therapeutic tissues TME TNBC trastuzumab triple-negative breast cancer tumor cells tumor microenvironment tumor-infiltrating vaccines virotherapy virus Wang Xu Zhang |
| 245 ## - TITLE STATEMENT | |
| Title | Breast Cancer Genetics, Immunology, and Immunotherapy |
| Remainder of title | An Interdisciplinary Approach. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Department of Clinical Immunology Karolinska Institutet Stockholm, Sweden | |
| Name of publisher, distributor, etc. | Springer Nature Switzerland AG | |
| Date of publication, distribution, etc. | 2024 |
| 490 ## - SERIES STATEMENT | |
| Series statement | Interdisciplinary Cancer Research |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Zusammenfassung: Genetics have a role in the presence of breast cancer, while the potential role of the immune system leads to consideration of immunotherapy in the treatment of the disease, particularly in metastatic triple-negative breast cancer. The sixth volume of the "Interdisciplinary Cancer Research" series, entitled "Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach" publishes comprehensive volumes on immune and genetic mechanisms of breast cancer diagnosis and prognosis. The role of molecular genetics, interleukins, chemokine receptor, and tumor-infiltrated lymphocytes-TILS in breast cancer are explained. Targeting myeloid determinants, SiRNA loaded in drug delivery nanosystems, nucleic acid and drug dual agent nanoplatforms, and oncolytic virotherapy are also discussed in the treatment of breast cancer, particularly in multidrug resistant and metastatic breast cancer. This interdisciplinary series is of special value to researchers working on immunology, genetics, and practitioners working on oncology. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value to researchers, oncologists, geneticists, and immunologists who wish to extend their knowledge on breast cancer |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Breast -- Cancer -- Genetic aspects -- Immunological aspects. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href=" https://doi.org/10.1007/978-3-031-65808-2 "> https://doi.org/10.1007/978-3-031-65808-2 </a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | E-BOOKS |
| Suppress in OPAC | |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Date acquired | Total checkouts | Barcode | Date last seen | Copy number | Uniform resource identifier | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 11/02/2024 | 20241102100521.0 | 11/02/2024 | 20241102100521.0 | https://doi.org/10.1007/978-3-031-65808-2 | 11/02/2024 | E-BOOKS |